Business Standard

Aurobindo Pharma scouting for suitable acquisitions in domestic market

Recently, through the acquisition of Sandoz's dermatology and oral solids business, Aurobindo has now entered the branded OTC segment in the US

Pharmaceuticals, drugs, pharma industry, medical, health, lab
Premium

Sohini DasSamreen Ahmad Mumbai/Bengaluru
Hyderabad-based Aurobindo Pharmaceuticals, which operates in the business-to-business (B2B) bulk drugs space in India, is scouting for acquisitions in the domestic market that would enable it to enter the branded generics segment here. Sources pointed out the company was looking for a potential acquisition in the range of Rs 30-40 billion, which would not only have a portfolio of pharma brands but also a strength of at least a few thousand medical representatives.

An e-mail sent to Aurobindo remained unanswered. Sources said Aurobindo had been looking for buys  in the Indian market for some time now, however, did not find

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 29 2018 | 5:31 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com